Merck V114-029

Mar 3, 2021

Started: 9/2018

Study Name: A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)

Indication: Pneumococcal

Principal Investigator: Luke Anschutz, Paul Bernhardson

This study is no longer active

Current Studies